Gmax Biopharm LLC.

Founded in 2010 and headquartered in Hangzhou, China, Gmax Biopharm LLC specializes in advanced biopharmaceuticals. The company has undergone strategic pivots to enhance its product offerings, primarily focusing on therapeutic monoclonal antibodies.Gmax Biopharm LLC specializes in the development of advanced biopharmaceutical products, focusing primarily on therapeutic monoclonal antibodies. Their main offerings include the GPCR Monoclonal Antibody Platform, targeting G protein-coupled receptors, and the M-Body Platform, designed to enhance the efficacy of antibody-based therapies. The US FDA has approved their product GMA131 for clinical studies aimed at treating Diabetic Kidney Disease (DKD). Additionally, GMA106, a second-generation monoclonal antibody for obesity, type 2 diabetes mellitus (T2DM), and non-alcoholic steatohepatitis (NASH), has progressed to the first human dosing stage.Gmax Biopharm generates revenue through strategic partnerships and clinical trials associated with their biopharmaceutical products. The company's operational model relies on collaborations with healthcare institutions and research organizations, allowing access to key products like GMA131 and GMA106. The company aims to introduce new products targeting chronic diseases and is actively exploring entry into additional European markets by late 2023.

1. Series C

   Mar 8, 2021

   Amount

   $78M

   Investors

   Locked

2. Series A

   Jan 22, 2017

   Amount

   Undisclosed

   Investors

   Locked